Prevention of Mother-To-Child Transmission of Hepatitis B Virus : Guidelines on Antiviral Prophylaxis in Pregnancy
Thieme. All rights reserved..
BACKGROUND: Most HBV-associated deaths among adults are secondary to infections acquired at birth or in the first five years of life.
AIM: To extend the guideline for the prevention of mother-to-child transmission of the hepatitis B virus to include antiviral prophylaxis.
METHODS: The guideline was developed by the World Health Organization (WHO) in accordance with WHO standards. The summary was translated into German by employees of the WHO Collaborating Centre at Danube University Krems (Austria).
RESULTS: In addition to the recommendation to test pregnant women for heptatitis B virus (HBV) and vaccinate newborns against hepatitis B as soon as possible after birth, two new recommendations have been formulated: pregnant women testing positive for HBV infection should receive tenofovir prophylaxis to prevent mother-to-child transmission of HBV. WHO recommends that in settings in which antenatal HBV DNA testing is not available, HBeAg testing can be used as an alternative to determine eligibility for tenofovir prophylaxis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) - 85(2023), 4 vom: 14. Apr., Seite 266-269 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Prävention der Mutter-zu-Kind-Übertragung des Hepatitis-B-Virus: Leitlinie zur antiviralen Prophylaxe während der Schwangerschaft |
|---|
| Beteiligte Personen: |
Harlfinger, Julia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 26.04.2023 Date Revised 26.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1630-7893 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347315615 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347315615 | ||
| 003 | DE-627 | ||
| 005 | 20231226033535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-1630-7893 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347315615 | ||
| 035 | |a (NLM)36216327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Harlfinger, Julia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention of Mother-To-Child Transmission of Hepatitis B Virus |b Guidelines on Antiviral Prophylaxis in Pregnancy |
| 246 | 3 | 3 | |a Prävention der Mutter-zu-Kind-Übertragung des Hepatitis-B-Virus: Leitlinie zur antiviralen Prophylaxe während der Schwangerschaft |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2023 | ||
| 500 | |a Date Revised 26.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a BACKGROUND: Most HBV-associated deaths among adults are secondary to infections acquired at birth or in the first five years of life | ||
| 520 | |a AIM: To extend the guideline for the prevention of mother-to-child transmission of the hepatitis B virus to include antiviral prophylaxis | ||
| 520 | |a METHODS: The guideline was developed by the World Health Organization (WHO) in accordance with WHO standards. The summary was translated into German by employees of the WHO Collaborating Centre at Danube University Krems (Austria) | ||
| 520 | |a RESULTS: In addition to the recommendation to test pregnant women for heptatitis B virus (HBV) and vaccinate newborns against hepatitis B as soon as possible after birth, two new recommendations have been formulated: pregnant women testing positive for HBV infection should receive tenofovir prophylaxis to prevent mother-to-child transmission of HBV. WHO recommends that in settings in which antenatal HBV DNA testing is not available, HBeAg testing can be used as an alternative to determine eligibility for tenofovir prophylaxis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Nußbaumer-Streit, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Gartlehner, Gerald |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) |d 1997 |g 85(2023), 4 vom: 14. Apr., Seite 266-269 |w (DE-627)NLM012669350 |x 1439-4421 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2023 |g number:4 |g day:14 |g month:04 |g pages:266-269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1630-7893 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2023 |e 4 |b 14 |c 04 |h 266-269 | ||